NANJING, China, October 9th, 2026 - Triastek, Inc. ("Triastek" or the "Company") announced that the Company and its wholly owned subsidiary, Triastek (Shanghai) Limited, have entered into a Collaboration and License Agreement with Johnson & Johnson^*. The collaboration aims to combine Johnson & Johnson's expertise in drug development with Triastek's 3D printing pharmaceutical technology and oral drug delivery capabilities for peptides and other therapeutic modalities to develop novel oral medicines. Johnson & Johnson will also make an equity investment in Triastek through its corporate venture capital organization, Johnson & Johnson Innovation - JJDC, Inc.

Triastek will leverage its MED&SSE (Melt Extrusion Deposition plus Semi-Solid Extrusion) 3D printing pharmaceutical technology and 3D Microstructure for Oral Macromolecules (3DμS®-OM) platform, combining room-temperature, low-shear manufacturing processes with the design of tablet structures and drug release profiles to address oral delivery challenges.

Dr. Senping Cheng, Founder and CEO of Triastek, said: "We greatly value the opportunity to collaborate with Johnson & Johnson. The collaboration, together with JJDC's investment, reflects a shared commitment to advancing the development of oral medicines. We look forward to working together to accelerate the development of next-generation oral medicines and ultimately translate innovation into clinical value for patients."

_{^*Legal entity: Janssen Pharmaceutica NV}

About Triastek

Global leader in 3D printing pharmaceuticals

Founded in July 2015, Triastek is dedicated to the mission of "revolutionizing the pharmaceutical industry, unlocking the next generation of medicine and benefiting patients worldwide." We have created the Melt Extrusion Deposition (MED®) 3D printing pharmaceutical process, transforming the delivery, development, and production of medicines through digital product development and continuous manufacturing.

Leveraging our proprietary 3D printing pharmaceutical technology, we design and develop transformative medicines for patients. Through collaboration with global pharmaceutical companies, we tackle challenging formulation problems, accelerating the development of new drug products and improving the quality of pharmaceuticals.

Our vision is to become the world's most influential intelligent pharmaceutical enterprise.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the Company's technology platforms, product development, collaborations, business strategies, and future business and operations. These statements are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties-including those related to pharmaceutical research and development, clinical trial results and timing, regulatory approvals, manufacturing scale-up, the performance of and actions taken by collaboration partners, competitive dynamics, and general economic and market conditions-that may cause actual results to differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any such statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.